GoAI
Get started
PAVmed Inc. logo

PAVmed Inc.

PAVM

NASDAQHealthcareMedical - Devices

Open in GoAI

Previous close

$5.175

−$0.005 · -0.10%

Aug 21, 4:00 PM ET

PAVM company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Strong Sell

Exit — multiple negative signals converging

Valuation

2

Overpriced

Momentum

22

Weakening

Sentiment

51

Mixed

Risk resilience

30

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

PAVmed Inc. operates as a U.S.-based medical technology firm. Its principal commercialized products include CarpX, a percutaneous device designed to address carpal tunnel syndrome. Other key offerings are EsoCheck, an esophageal cell collection device vital for the early detection of esophageal adenocarcinoma and Barrett's Esophagus (BE), and EsoGuard, a specialized bisulfite-converted next-generation sequencing DNA assay. The company's extensive development pipeline further encompasses EsoCure, an esophageal ablation device intended to treat dysplastic BE; PortIO, an implantable intraosseous vascular access device; and NextFlo, a disposable infusion platform technology. Also in development are the Veris cancer healthcare platform, which features an intelligent vascular port for combined remote monitoring and data analytics, alongside Veris cardiac monitors. Additional innovations include NextVent single-use ventilators, FlexMO medical circulatory support cannulas, DisappEAR resorbable pediatric ear tubes, and Solys for noninvasive glucose monitoring. Established in 2014, the enterprise originally traded as PAXmed Inc. before rebranding to PAVmed Inc. in April 2015. Its corporate headquarters are located in New York, New York.

Industry
Medical - Devices
Sector
Healthcare
Headquarters
US
CEO
Lishan Aklog
Listed since
Jul 27, 2016
Employees
41

Market position

Day range

Current $5.175

52-week range

Current $5.175

Open
$5.42
Previous close
$5.18
Volume
6.03K
0.25× average
Average volume
24.17K
Average daily volume
Market cap
33.03M USD
Beta
0.52
Market reference 1
50-day average
$5.1774
-0.05% below average
200-day average
$8.0284
-35.54% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
16.25M USD
P/E (TTM)
-0.32×
P/B (TTM)
0.93×
P/S (TTM)
294.93×
EV / EBITDA
-6.93×
Earnings yield
9.03%
Free cash flow yield
-117292.28%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
-254.46%
Operating margin
-23842.86%
Net margin
-10794.64%
Return on equity
1.18%
Return on assets
1.03%
Return on invested capital
-61.17%

Financial health

Debt / equity
0.49×
Current ratio
0.17×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends4533%-8284%-21100%-33917%Gross margin, FY2021: -17.00%Gross margin, FY2022: -858.62%Gross margin, FY2023: -161.83%Gross margin, FY2024: -101.60%Gross margin, FY2025: -354.93%Operating margin, FY2021: -10878.60%Operating margin, FY2022: -24161.01%Operating margin, FY2023: -2805.67%Operating margin, FY2024: -1485.38%Operating margin, FY2025: -30712.68%Net margin, FY2021: -10069.40%Net margin, FY2022: -23602.92%Net margin, FY2023: -2617.25%Net margin, FY2024: 1328.58%Net margin, FY2025: 564.79%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 -17.00%. Gross margin FY2022 -858.62%. Gross margin FY2023 -161.83%. Gross margin FY2024 -101.60%. Gross margin FY2025 -354.93%. Operating margin FY2021 -10878.60%. Operating margin FY2022 -24161.01%. Operating margin FY2023 -2805.67%. Operating margin FY2024 -1485.38%. Operating margin FY2025 -30712.68%. Net margin FY2021 -10069.40%. Net margin FY2022 -23602.92%. Net margin FY2023 -2617.25%. Net margin FY2024 1328.58%. Net margin FY2025 564.79%.

Income trends

Revenue

71K USD-97.63%

Operating income

−21.81M USD+50.98%

Net income

401K USD-98.99%
Income trends across reported periods52.88M USD527.6K USD−51.82M USD−104.17M USDRevenue, FY2021: 500K USDRevenue, FY2022: 377K USDRevenue, FY2023: 2.45M USDRevenue, FY2024: 3M USDRevenue, FY2025: 71K USDOperating income, FY2021: −54.39M USDOperating income, FY2022: −91.09M USDOperating income, FY2023: −68.8M USDOperating income, FY2024: −44.49M USDOperating income, FY2025: −21.81M USDNet income, FY2021: −50.35M USDNet income, FY2022: −88.98M USDNet income, FY2023: −64.18M USDNet income, FY2024: 39.79M USDNet income, FY2025: 401K USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 500K USD. Revenue FY2022 377K USD. Revenue FY2023 2.45M USD. Revenue FY2024 3M USD. Revenue FY2025 71K USD. Operating income FY2021 −54.39M USD. Operating income FY2022 −91.09M USD. Operating income FY2023 −68.8M USD. Operating income FY2024 −44.49M USD. Operating income FY2025 −21.81M USD. Net income FY2021 −50.35M USD. Net income FY2022 −88.98M USD. Net income FY2023 −64.18M USD. Net income FY2024 39.79M USD. Net income FY2025 401K USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue71K USD3M USD2.45M USD377K USD500K USD
Cost of goods sold323K USD6.04M USD6.42M USD3.61M USD585K USD
Gross profit−252K USD−3.04M USD−3.97M USD−3.24M USD−85K USD
Research and development4.49B USD5.93M USD14.28M USD25.34M USD19.85M USD
Selling, general, and administrative17.17B USD36.15M USD48.53M USD60.73M USD34.32M USD
Operating expenses21.55M USD41.44M USD64.83M USD87.85M USD54.31M USD
Interest income29K USD254K USD505K USD169K USD—
Interest expense21K USD45K USD589K USD1.28M USD—
Depreciation and amortization105K USD1.2M USD2.93M USD2.46M USD226K USD
Operating income−21.81M USD−44.49M USD−68.8M USD−91.09M USD−54.39M USD
Net income401K USD39.79M USD−64.18M USD−88.98M USD−50.35M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
55%
6 beats, 5 misses, 0 met estimates
Average EPS surprise
-27.75%
11 comparable reports
Latest EPS result
-0.87
Estimate -0.47 · Miss by 85.11%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-0.4-8.25-16.09-23.94Q1 '25BeatQ2 '25BeatQ3 '25MissQ4 '25MissQ1 '26BeatQ2 '26MissQ3 '26MissQ4 '26Estimate
Q1 2025, reported Mar 24, 2025: actual -1.8, estimate -3.3, surprise +45.45%, Beat. Q2 2025, reported May 14, 2025: actual -2.1, estimate -8.71, surprise +75.89%, Beat. Q3 2025, reported Aug 14, 2025: actual -22.2, estimate -3.9, surprise -469.23%, Miss. Q4 2025, reported Nov 13, 2025: actual -8.7, estimate -5.1, surprise -70.59%, Miss. Q1 2026, reported Mar 26, 2026: actual -2.05, estimate -4.5, surprise +54.44%, Beat. Q2 2026, reported May 15, 2026: actual -4.42, estimate -0.69, surprise -540.58%, Miss. Q3 2026, reported Aug 14, 2026: actual -0.87, estimate -0.47, surprise -85.11%, Miss. Q4 2026, reported Nov 12, 2026: actual —, estimate -0.63, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates79.52K54.43K29.34K4.25KQ1 '25MissQ2 '25MissQ3 '25MissQ4 '25MissQ1 '26BeatQ2 '26MissQ3 '26MissQ4 '26Estimate
Q1 2025, reported Mar 24, 2025: actual 10K USD, estimate 20K USD, surprise -50.00%, Miss. Q2 2025, reported May 14, 2025: actual 8K USD, estimate 10K USD, surprise -20.00%, Miss. Q3 2025, reported Aug 14, 2025: actual 6K USD, estimate 10K USD, surprise -40.00%, Miss. Q4 2025, reported Nov 13, 2025: actual 5K USD, estimate 12.5K USD, surprise -60.00%, Miss. Q1 2026, reported Mar 26, 2026: actual 52K USD, estimate 25K USD, surprise +108.00%, Beat. Q2 2026, reported May 15, 2026: actual 22K USD, estimate 74K USD, surprise -70.27%, Miss. Q3 2026, reported Aug 14, 2026: actual 33K USD, estimate 48K USD, surprise -31.25%, Miss. Q4 2026, reported Nov 12, 2026: actual —, estimate 25K USD, surprise —, Comparison unavailable.

Corporate actions

Corporate action history

Stock split

Effective Jan 2, 2026

1:30

Stock split

Effective Dec 7, 2023

1:15

PAVM peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding PAVM

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
304.94K
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
iShares Micro-Cap ETF logoiShares Micro-Cap ETFIWC
Market value
82K
Weight
0.01%
AUM
1.53B USD
Expense ratio
0.60%
Price / 1D
$198.39+1.10%

Continue in GoAI

Research PAVM

research.disclaimer